Opportunities in China

Are you interested in exploring potential possibilities in China market? Here are a few leading companies from China seeking  potential investment or collaboration partners: Company 1

  • Industry: Medical Device
  • Interest: Injection and infusion consumables, wound care consumables, orthopaedic, blood purification equipment and consumables, minimally invasive intervention consumables, Intelligent equipment

Company 2

  • Industry: Therapeutics
  • Interest: Drugs in liver disease or diabetes spaces, developing in Canada is preferred.

Please contact us for further information. You could also attend our China Focus@BIO Philadelphia to schedule 1-to-1 meetings with above-mentioned companies. Early bird rate is still available now.

Register & Schedule 1-1 Meetings

 

 

Confirmed Speakers

Katherine Andersen
Head of Healthcare Corporate Finance and East/Central Life Science
Silicon Valley Bank
Kim Nearing
Managing Director
Cedrus Group
Andrew Nerlinger
Bill Wood Ventures
Venture Partner
Daniel Chai
Turret Capital
Managing Partner
Mark Tang
Managing Director
Good Health Capital
Tim Xiao
Principal
Delos Capital
Michael Song
Medimmune
Sr. Manager
Brad Loncar
Loncar Investment
CEO
Ping Cao
Henlius Biotech
VP business development
Gurkeerat Singh
Lilly Research Laboratories
VP Emerging Technology and Innovation
Become a Speaker

Innovation Competition

Upcoming Preliminaries: 

  • April 30, Online
  • June 2, Philadelphia

What you can get?

  • The opportunity for media coverage and promotion on our English and Chinese platforms.
  • 1-to-1 partnering opportunities with potential Chinese investors.
  • Exhibition space for your company at China Focus forum with a surprise discount.
  • The opportunity for a 5-day sponsored business development trip in China to meet 100+ investors and corporate executives.

Click here to get more information about preliminary schedule and featured prizes.

Submit Application

 

Cross-border Investment News

Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders

  • Series A financing led by two leading global venture capital firms – Sequoia Capital China and Highlight Capital

Upcoming Event